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Protein destruction: Adapting roles for Cks proteins
J. Wade Harper
Cks1, a subunit of cyclin-dependent kinases, has now
been identified as an essential cofactor in the
ubiquitination of the Cdk inhibitor p27 by the SCFSkp2
ubiquitin ligase. This activity, which can be independent
of Cdk binding, links Cks to positive growth control
pathways regulating the G1/S transition and to cancer.
Address: Department of Biochemistry and Molecular Biology, Baylor
College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
E-mail: jharper@bcm.tmc.edu
Current Biology 2001, 11:R431–R435
0960-9822/01/$ – see front matter 
© 2001 Elsevier Science Ltd. All rights reserved.
Cyclin-dependent kinases (Cdks) regulate the cell divi-
sion cycle. These kinases are composed of a catalytic Cdk
subunit and a regulatory cyclin subunit; certain Cdks,
including Cdk1 (Cdc2) and Cdk2, also form tight com-
plexes with a small (9–18 kDa) protein known generically
as the Cdc kinase subunit (Cks). While it has been clear
for more than a decade that Cks proteins are essential for
Cdk function and cell division in yeast, their precise
functions have remained poorly understood (reviewed in
[1]). Now, new experiments published in Molecular Cell [2]
and Nature Cell Biology [3] have uncovered a role for one of
the two mammalian Cks proteins, p9Cks1, in facilitating
the ubiquitin-mediated proteolysis of the Cdk inhibitor
p27 via interaction with the SCFSkp2 ubiquitin ligase.
Unex-pectedly, this activity appears to be independent of
Cks1’s interaction with Cdk2. This work also reveals a
specific role for Cks1 in controlling the G0–G1 transition,
and suggests that Cks1 might be a regulatory target for
controlling cell division during both development and
transformation.
Cks proteins were originally identified as suppressors of
mutations in the fission and budding yeast Cdk1 genes
[4,5]. Biochemical experiments revealed that this suppres-
sion reflects the physical association of the budding yeast
Cks1 and fission yeast p13suc1+ proteins with Cdk1 and
with active cyclin–Cdk1 complexes [5,6]. Subsequent
isolation of human Cks1 and Cks2 [7] revealed that Cks
proteins are structurally and functionally conserved
throughout eukaryotes, and that they associate specifically
with Cdk1, Cdk2 and Cdk3. We now know through a
series of structural studies that Cks and cyclin proteins
interact simultaneously and independently with Cdks [8]
(reviewed in [1]).
How do Cks proteins control Cdk function? Much of our
understanding of Cks function has come from analysis of
mutants in yeast and from biochemical experiments in
Xenopus extracts. Cks proteins, when associated with Cdks,
do not act as inhibitors or activators in the classic sense,
but seem to modulate substrate choice or the extent of
phosphorylation. Certain Cks1 mutations lead to cell-cycle
arrest in G1, and this appears to reflect defects in G1
cyclin–Cdk1 activity towards important substrates, such as
the Cdk inhibitors Sic1 and Far1 [9,10]. 
Removal of Cks function, either in yeast or Xenopus
extracts, can also lead to defects in the entry into, passage
through and exit from mitosis [9,11]. In general, this
seems to reflect the fact that Cks1 enhances phosphory-
lation of various mitotic Cdk1 substrates, including
Cdc25, Wee1 and components of the anaphase-promot-
ing complex. Precisely how Cks1 facilitates phosphoryla-
tion of Cdk targets is not known, but it is conceivable
that certain phosphorylated proteins can interact with a
putative phosphate-binding surface on Cks1 [8], and in
this context, such target proteins are phosphorylated
more efficiently by the associated Cdk. Finally, inactivation
of mitosis-promoting factor (MPF) via destruction of
cyclin B is rate limiting for exit from mitosis. Here, Cks1
also plays a role by helping target ubiquitinated cyclin B
to the proteasome for degradation, as demonstrated
in budding yeast [12]. Consistent with this, recent work
in Caenorhabditis elegans [13] indicates that one of the two
Cks proteins in this organism, Cks1, is also required
for mitotic exit, as well as for completion of maternal
meiotic divisions.
Now, just when we thought we were beginning to under-
stand how Cks1 functions in mitosis, new data have
emerged that link Cks1 to the destruction of the Cdk
inhibitor p27 by the SCFSkp2 ubiquitin ligase. p27 acts as a
negative regulator of the G1–S transition by binding to
cyclin E–Cdk2 and to cyclin A–Cdk2. These kinases control
the S-phase program, and cyclin E–Cdk2 also controls cen-
trosome duplication, although the molecular details of these
activities are sketchy. Two mechanisms combine to elimi-
nate p27 activity during G1 (reviewed in [14]; Figure 1).
First, the assembly of cyclin D–Cdk4 in response to mito-
gens requires p27 or its relatives, p21 and p57. Accumula-
tion of cyclin D–Cdk4–p27 occurs at the expense of a
portion of the cyclin E–Cdk2–p27 complexes present in
G1. Thus, partial activation of Cdk2 is achieved by seques-
tration of p27 by cyclin D–Cdk4. Partial Cdk2 activation
then facilitates phosphorylation of p27 on threonine residue
T187 [14]. This event targets p27 for ubiquitin-mediated
proteolysis [15] through the SCFSkp2 ubiquitin ligase
[16–18], thereby eliminating Cdk2-associated p27.
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SCF complexes are composed of Skp1, Cul1, Rbx1, and a
member of the F-box family of proteins [18–21]. These
complexes act as E3 ubiquitin ligases in conjunction with
E2 ubiquitin conjugating enzymes and an E1 ubiquitin
activating enzyme. F-box proteins are modular substrate
specific receptors of ubiquitination targets. They interact
with the core ubiquitin ligase through the F-box motif and
with substrates via carboxy-terminal protein–protein inter-
action domains, including a leucine-rich repeat (LRR)
domain in the case of Skp2 (Figure 2a). SCF substrates
typically interact with their specific F-box proteins in a
phosphorylation dependent manner. Several lines of evi-
dence indicate a role for SCFSkp2 in p27 destruction. First,
cell extracts lacking Skp2 — either derived from G1 cells
or generated by Skp2 immunodepletion — are deficient in
p27 ubiquitination activity, but addition of recombinant
Skp2 reconstitutes phosphorylation-dependent ubiquiti-
nation [16,18]. Second, Skp2 interacts specifically with the
T187 phosphorylated form of p27 in crude cell or reticulo-
cyte extracts. Third, cells from Skp2–/– mice accumulate
p27 in the T187 phosphorylated form, and this is reversed
by expression of Skp2 [22]. Fourth, Skp2 immune com-
plexes supplemented with E1 and E2 activity catalyze p27
ubiquitination [16].
Although these data support a role for Skp2 in p27
turnover, several questions have remained unanswered.
Most notable was the fact that insect-cell-derived SCFSkp2
is inefficient at catalyzing p27 ubiquitination, unlike its
yeast cousin SCFCdc4, which is responsible for ubiquitina-
tion of the Sic1 Cdk inhibitor [19,20]. Moreover, although
T187-phosphorylated p27 can interact with Skp2 in crude
extracts, it cannot do so with purified Skp2, indicating the
existence of another factor or modification important for
p27 ubiquitination. To solve this problem, Hershko, Pagano
and co-workers [3] searched for proteins in crude cell
extracts that activate p27 ubiquitination by recombinant
SCFSkp2, and found none other than Cks1. An independent
solution to this puzzle came from the work of Reed and co-
workers [2], who found that deletion of Cks1 in the mouse
leads to viable animals that are smaller than heterozygous
littermates, a phenotype reminiscent of mice lacking Skp2
[22]. Analysis of Cks1–/– cells revealed dramatic accumula-
tion of T187-phosphorylated p27. This suggested that p27
ubiquitination was being blocked at a step after its phos-
phorylation. Consistent with this, Cks1–/– extracts were
defective in p27 ubiquitination, but the reaction could be
reconstituted by addition of recombinant Cks1.
Previous work had demonstrated that ubiquitination of
p27 by SCFSkp2 requires that it be assembled with either
cyclin E–Cdk2 or cyclin A–Cdk2 [23,24]. As Cdk2 inter-
acts with Cks1, one could imagine a scenario in which
association of Cks1 with Cdk2 is required to assemble the
p27–cyclin E–Cdk2 complex onto SCFSkp2. To examine
this question, Spruck et al. [2] employed a mutant Cks1
protein that does not bind Cdk2, Cks1(E63Q). Surpris-
ingly, this mutant protein supported p27 ubiquitination to
Figure 1
Integration of Skp2 and Cks1 into the G1
regulatory pathway. Cells respond to mitogens
by inducing the expression of D-type cyclins,
which assemble with Cdk4 via sequestration
of p27. These cyclin D–Cdk4 complexes
participate in the inactivation of Rb and the
activation of E2F, which promotes S phase.
p27 sequestration results in partial activation
of cyclin E–Cdk2, which in turn
phosphorylates p27 contained in existing
cyclin E–Cdk2 complexes. This
phosphorylation event targets p27 for
destruction via the SCFSkp2 ubiquitin ligase in
a process that requires Cks1. Although not
shown, cyclin A–Cdk2–p27 complexes are
likely to be produced under the same control
pathways. Skp2 and Cks1 are both expressed
in a cell-cycle-regulated manner and are
therefore downstream of growth promoting
signals. Cks1 expression is regulated by
growth inhibitory pathways mediated by
TGF-β. Cyclin D and Skp2 levels are
frequently induced in cancer while p27 levels
are frequently reduced. Induction of Cks1 may
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a level almost as high as wild-type Cks1, suggesting that
the mechanism of activation can be Cdk2 independent.
How then does Cks1 participate? Work from both groups
indicates that Cks1 enhances the interaction of phosphory-
lated p27 with Skp2. However, precisely how Cks does
this is not clear. One possibility is that binding of Cks to
Skp2 promotes a structural change that facilitates the
interaction of phosphorylated p27 with Skp2 (Figure 2a,
model A). This idea is suggested by the finding that Cks1
can associate with Skp2 [2,3] independent of its associa-
tion with Cdks [2]. The presumptive substrate-binding
surface in Skp2, the LRRs, are occluded by a carboxy-
terminal strand of Skp2 [25]. Given the precedent of other
LRR interactions, this strand would need to be nudged
away in order for p27 recognition and Cks1 might fulfill
this task. One distinguishing feature of this model is that
Cks1 functions independently of both Cdk2 and p27.
Alternatively, Cks1 might physically bridge p27 and Skp2.
Here, two extremes are possible. In one case, Cks1 inter-
acts in a phosphorylation-dependent manner with p27
while simultaneously binding Skp2 (Figure 2a, model C).
This model is suggested by the finding that Cks1 binds to
phosphorylated p27 but not unphosphorylated p27 in vitro
[3]. However, it is not clear at present whether this interac-
tion is relevant to ubiquitination or is simply a byproduct
of the fact that Cks1 contains a phosphate-binding site.
Thus far, only a single p27 phosphopeptide has been
examined for interaction with Cks1 and it is not clear
whether Cks1 is simply recognizing the phosphate group
or whether there are additional specific interactions, as
would be anticipated if this is a physiologically relevant
interaction. In this regard, analysis of the interaction of
Cks2 with phospho-p27 might be informative since this
protein retains the phosphate binding site (Figure 2b) but
does not support p27 ubiquitination or bind Skp2 [2,3]. In
the second case, Cks1 may interact simultaneously with
Skp2 and p27 and allow specificity recognition of
phospho-T187 by Skp2 (Figure 2a, model B).
While, in principle, both bridging models could be Cdk
independent, we cannot yet exclude the possibility that
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Figure 2
(a) Models depicting possible roles for Cks1 in p27 destruction. Skp2
is synthesized during late G1 and S-phase and assembles into an SCF
complex containing Skp1, Rbx1 and Cul1, which is covalently modified
by a single Nedd8 protein. This complex is competent to engage an E2
ubiquitin conjugating enzyme, such as Cdc34. Based on the crystal
structure of the Skp1–Skp2 complex [25], the carboxyl terminus of
Skp2 covers the concave face of the leucine rich repeat (LRR) motif,
likely blocking access of substrates to their interaction surface. Binding
of phosphorylated p27 requires Cks1, which can interact with both
Skp2, p27 and Cdk2. Three models are depicted. In model A, Cks1
binds Skp2 independent of its interaction with Cdk2, and this induces
a conformational change that reveals the LRR surface, allowing p27 to
bind to Skp2 in a phosphorylation-dependent manner. In model B,
Cks1 interacts simultaneously with Cdk2 and Skp2, thereby facilitating
the interaction of phosphorylated p27 with the LRRs. In model C, Cks1
interacts simultaneously with Cdk2, Skp2, and p27. The interaction
with phosphorylated p27 occurs through a phosphate-binding site
located on the surface of Cks1. (b) Comparison of Cks1 and Cks2
structures. Upper panel: Cks1 and Cks2 both have a phosphate-
binding site composed of Lys11, Arg20, Trp54 and Arg71 (in yellow),
on a surface opposed to the Cdk interaction surface. Lower panel:
major differences in the structures of Cks1 and Cks2 exist on a surface
containing helices 1 and 2 and the carboxy-terminal tail. Identical
residues are shown in gray, conservative changes in orange, and non-
conservative changes in red. Glu63, which when mutated to glutamine
blocks interaction with Cdk2 but not with SCFSkp2, is shown in green.



























































the form of Cks1 used in p27 ubiquitination in vivo is actu-
ally the Cdk bound form (Figure 2a, models B and C). In
its complex with cyclin E–Cdk2–p27, Cks1 could simulta-
neously contact p27 and Skp2, thereby holding one or
both proteins in a conformation appropriate for interaction.
Moreover, both cyclins A and E have been demonstrated
to interact with Skp2, so in principle, addition contacts
may exist in the complex. The use of multiple interaction
sites provides the basis for the exquisite specificity seen in
ubiquitination reactions and provides a simple biophysical
explanation for why free p27 is a relatively poor ubiquiti-
nation substrate. 
It is also likely that the precise docking of the p27 complex
with SCFSkp2 is important for orienting the relevant lysine
residues in p27 for ubiquitin transfer. Thus, the role of
Cks1 may go beyond simply facilitating binding of sub-
strate and SCF. Obviously, structural analysis of the
complex will be required to determine the overall contri-
butions of these various interactions and whether Cks1
function is Cdk independent or not. In addition, it is clear
that many targets of ubiquitin ligases are components of
multiprotein complexes. It seems likely that much of the
specificity in these cases reflect multisubunit interactions,
many of which do not involve the protein that is targeted
for ubiquitination.
Mammals and C. elegans both have two Cks homologs. As
mentioned above, Cks2 is unable to support p27 ubiquiti-
nation, despite the fact that it is 87% similar to Cks1. But
the fact that Cks1 mice are viable indicates that Cks2 may
be largely redundant with Cks1, especially for progression
through mitosis. The Cdk-binding and phosphate-binding
surfaces, which are derived from the four-stranded β sheet
region, are conserved in Cks proteins (Figure 2b). In con-
trast, the major structural differences are located on the two
α helices and also at the carboxyl terminus, which generate
a largely contiguous surface (Figure 2b). It is likely that
these regions perform Cks-specific functions, such as Skp2
binding in the case of Cks1. Given the selectivity of Cks1
in promoting p27 ubiquitination, it seems likely that Cks2
may also function in one or more pathways that are non-
redundant with Cks1. Thus, an analysis of mice lacking
Cks2 and both Cks proteins is anxiously awaited.
The implications of this new work go well beyond
mechanistic details of p27 ubiquitination. It is now widely
appreciated that p27 functions to control cell-cycle exit
during development, and as such it is a target for inactiva-
tion during transformation. Although mutations in the p27
structural gene are rare, p27 levels and localization are
nevertheless altered in several classes of human tumors,
including breast and prostate cancer. It is currently believed
that alterations in p27 proteolysis are central to its removal
during sporadic transformation. Overexpression of Skp2
can promote S-phase entry in quiescent fibroblasts in a
manner that is blocked by non-phosphorylatable p27 [17]
and Skp2 can collaborate with oncogenes such as Ras to
transform cells in the lymphoid compartment [26]. More-
over, it has recently been demonstrated that Skp2 is
induced in multiple tumor types and this correlates with
reduced levels of p27 in such tumors [26].
Like Skp2, Cks1 expression is growth regulated; its
mRNA is absent during G1 but present during S phase [7].
Thus, one would imagine that inactivation of p27 in cancer
via the ubiquitin pathway would require, not only the
induction of Skp2, but of Cks1 as well. In this regard,
epithelial cells shut-off Cks1 transcription in response to
the growth inhibitor TGF-β [27]. Given this link, it is
tempting to speculate that other negative growth regula-
tory pathways will function by limiting the levels of Skp2
and/or Cks1 (Figure 1). Conversely, it is plausible that the
Skp2 and Cks1 genes are coordinately activated in order to
ensure that the two proteins are both present at the appro-
priate time in the cell cycle to catalyze p27 destruction.
Understanding how these pathways are altered during
transformation will be a challenge for the future.
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